Tuberculosis is treated with a combination of antibiotics taken over several months. The standard course for active, drug-susceptible TB lasts 6 to 9 months and is split into two phases: an intensive phase using four drugs, followed by a continuation phase using two. With proper treatment, the global success rate for drug-susceptible TB is 88%.
How your treatment looks depends on whether you have active TB disease or latent TB infection, and whether the bacteria respond to standard medications.
Active TB: The Standard 6- to 9-Month Regimen
Active TB disease is treated with four antibiotics working together. The reason for using multiple drugs at once is simple: TB bacteria are stubborn, and a single drug gives them an opportunity to develop resistance. The four first-line medications are isoniazid, rifampin, pyrazinamide, and ethambutol, often abbreviated as RIPE.
Treatment is divided into two phases. During the intensive phase, you take all four drugs daily for 8 weeks. The goal is to kill the bulk of the bacteria quickly and reduce how contagious you are. Most people are no longer infectious after a few weeks of this phase, though treatment continues far beyond that point.
The continuation phase follows, lasting either 18 weeks or longer depending on your situation. During this phase, you take only isoniazid and rifampin. The total treatment time adds up to 6 to 9 months. The exact duration, dose frequency, and number of doses your provider prescribes will vary. Some people take medication daily, others five days a week, and some shift to two or three times weekly during the continuation phase.
It’s critical to finish the entire course even after you feel better. Stopping early is one of the main reasons TB becomes drug-resistant.
Treating Latent TB Infection
Latent TB means the bacteria are in your body but dormant. You aren’t sick and can’t spread it to others, but without treatment, latent TB can become active disease later. Treating it is preventive, and the regimens are shorter and simpler than those for active TB.
The CDC recommends several short-course options:
- 3HP (3 months, once weekly): A combination of isoniazid and rifapentine taken once a week for 12 total doses. This is one of the most convenient options and is recommended for most people aged 2 and older, including many people living with HIV.
- 4R (4 months, daily): Rifampin alone, taken daily for 120 doses. This is a good choice for people who can’t tolerate isoniazid or who were exposed to isoniazid-resistant bacteria. It’s recommended for both children and adults who are HIV-negative.
- 3HR (3 months, daily): Isoniazid and rifampin together, taken daily for 90 doses. Suitable for children and adults, including some people with HIV depending on their other medications.
Your provider will choose a regimen based on your age, HIV status, other medications you take, and the resistance pattern of the TB strain you were exposed to. Some of these regimens interact with antiretroviral drugs, so the choice matters if you’re living with HIV.
Drug-Resistant TB
When TB bacteria don’t respond to at least isoniazid and rifampin, the two most important first-line drugs, the condition is classified as multidrug-resistant TB (MDR-TB). This requires a completely different treatment approach.
The World Health Organization now recommends a 6-month all-oral regimen called BPaLM as the preferred option for most people with MDR-TB. It combines four medications: bedaquiline, pretomanid, linezolid, and moxifloxacin. If testing shows the bacteria are also resistant to fluoroquinolones, moxifloxacin is dropped and treatment continues with the remaining three drugs (known as BPaL).
This is a significant improvement over older MDR-TB regimens, which could last 18 to 20 months and often involved injectable drugs with harsh side effects. The 6-month oral regimen is easier on patients and has better outcomes.
TB Treatment When You’re Living With HIV
TB and HIV frequently occur together, and managing both infections at the same time requires careful coordination. Everyone with HIV and active TB should be on antiretroviral therapy (ART), but the timing of when to start ART depends on how suppressed the immune system is.
If your immune cell count is very low (below 50 CD4 cells), ART should start within 2 weeks of beginning TB treatment. If your count is higher, ART typically begins within 2 to 8 weeks. For TB meningitis, a more cautious approach is needed. ART is usually delayed until at least 2 weeks into TB treatment, after the brain infection is under control, to reduce the risk of dangerous inflammation.
Side Effects to Watch For
TB medications are effective, but they carry real side effects that you should know about before starting treatment. The most important ones involve your liver, your eyes, and your nerves.
Liver damage (hepatotoxicity) is the most serious concern. Isoniazid, pyrazinamide, and rifampin can all stress the liver. Warning signs include yellowing of the skin or eyes, dark brown urine, light-colored stool, persistent nausea, vomiting, abdominal pain, unexplained fatigue, or a fever lasting three or more days. If you notice any of these, stop taking the medication and contact your provider immediately for blood work.
Ethambutol can cause eye problems, specifically a type of nerve damage called optic neuritis. You might notice blurred vision or changes in how you see colors. This is why vision checks are part of routine monitoring during treatment.
Isoniazid can cause tingling, numbness, or pain in the hands and feet, a condition called peripheral neuropathy. To prevent this, many providers prescribe vitamin B6 (pyridoxine) alongside isoniazid, especially if you’re pregnant, breastfeeding, living with HIV, or have diabetes or kidney problems.
At a minimum, you should expect monthly check-ins with your provider throughout treatment. These visits are for catching side effects early, reviewing how you’re tolerating the drugs, and adjusting the plan if needed.
Why Directly Observed Therapy Matters
TB treatment only works if you take every dose. Missing doses or stopping early allows the bacteria to survive and potentially develop resistance, which puts both you and the people around you at risk. That’s why health systems worldwide rely on a strategy called directly observed therapy, or DOT.
With DOT, a healthcare worker or trained person watches you take each dose of your medication. This isn’t about trust. The CDC recommends DOT for all patients with TB disease, including children, because there’s no reliable way to predict who will stick with a months-long regimen without support. During each session, the observer also checks in on how you’re feeling and whether you’re experiencing side effects.
DOT doesn’t have to mean showing up at a clinic every day. It can happen wherever is convenient for you, and many programs now offer electronic DOT (eDOT), where you take your medication over a video call using a smartphone, tablet, or computer. The flexibility makes it easier to keep up with treatment without disrupting your daily life.
Treatment for Children
Children with TB receive the same core drugs as adults, but doses are calculated by weight rather than given in fixed amounts. For children under 25 kg, child-friendly dispersible tablets are preferred because they can be dissolved in water, making them much easier to swallow. Older children weighing 25 to 35 kg can use either dispersible or adult tablet formulations, and switching to adult pills at that stage reduces the number of tablets they need to take.
For very young children under 5 kg, dosing accounts for both age and weight, since the body processes drugs differently in the first few months of life. Children under 3 months may need adjusted doses of certain medications. For severely ill children who can’t swallow, dispersible tablets can be given through a nasogastric tube.